Can-Fite BioPharma Ltd. CANF
What this company does
Written from the business description in Can-Fite BioPharma Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.
Revenue compounded at −11.9% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity lost 178 cents this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | · | · | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −5.97 | −10.86 | −17.92 | −0.01 | −0.03 | −0.04 | −0.14 | −0.17 |
| Dividend / sh $ | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | −21 | −5 | · | · |
| ROE % | −178.2 | −134.9 | −142.5 | −107.9 | −123.3 | −339.2 | −462.7 | −219.1 |
| Shares out B | 0.00 | 0.00 | 1.36 | 0.82 | 0.82 | 0.46 | 0.12 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 9 of 19 fiscal years. 45 checks could not be computed.